Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 3,176

Document Document Title
WO/2021/032934A1
The present invention provides compounds of formula (I) compositions comprising such compounds; the use of such compounds in therapy; and methods of treating patients with such compounds; wherein A, B, and, n, are as defined herein.  
WO/2021/013800A1
The invention relates to substituted N-phenyl-N-aminouracils of general formula (I) or salts thereof, wherein the groups in general formula (I) are as defined in the description, and to the use thereof as herbicides, in particular for co...  
WO/2021/000041A1
The present document describes compounds, or pharmaceutically acceptable salt thereof, of a core formula (I) Wherein R1 includes an amino group. These compounds are particularly useful in the formulation and in vivo and ex vivo delivery ...  
WO/2020/263994A1
The present invention discloses a liquid, propellant-free pharmaceutical formulation and a method for administering a pharmaceutical preparation by nebulizing the pharmaceutical preparation in an inhaler. The propellant-free pharmaceutic...  
WO/2020/252589A1
The present document describes compounds, or pharmaceutically acceptable salt thereof, of a core formula (I) where R1 features an amine group, particularly useful in the formulation of lipid particles including nucleic acid therapeutic a...  
WO/2020/248076A1
Disclosed are methods for separating, recovering, and purifying cannabidiolic acid (CBDA) salts from an organic solvent solution comprising a mixture of cannabinoids. The methods comprise solubilizing the mixture of cannabinoids in C5-C7...  
WO/2020/248077A1
Disclosed are methods for separating, recovering, and purifying tetrahydrocannabinolic acid (THCA) salts from an organic solvent solution comprising a mixture of cannabinoids. The methods comprise solubilizing the mixture of cannabinoids...  
WO/2020/252222A1
Provided herein are compounds that modulate progranulin and methods of using the compounds in progranulin-associated disorders, such as Frontotemporal dementia (FTD).  
WO/2020/216766A1
The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, solvates, hydrates, tautomers or stereoisomers thereof, wherein R1, R2, R2a, R3, Ra2, Ra4, Ra5, Ra6, Ra7, X1, X1a, A1 and A2 have the meaning...  
WO/2020/117637A1
The present invention is directed to derivatives and prodrugs of quinuclidine-ring containing compounds. The present invention is further directed to ophthalmo!ogical compositions comprising a therapeutically effective amount of a compou...  
WO/2020/096909A1
Provided herein is a bulk composition comprising the trihydrate form of (3S, 4R, 3'R)-6-[4-(4-amino-5-chloro-2-methoxy-benzoylamino)-3-methox y-piperidin-1-yl]-hexanoic acid 1-azabicyclo[2.2.2]oct-3'-yl ester di-hydrochloride salt. Provi...  
WO/2020/096911A1
Provided herein are methods of producing the trihydrate form of (3S, 4R, 3'R)-6-[4-(4-amino-5-chloro-2-methoxy-benzoylamino)-3-methox y-piperidin-1-yl]-hexanoic acid 1-azabicyclo[2.2.2]oct-3'-yl ester di-hydrochloride salt.  
WO/2020/039092A3
The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haemat...  
WO/2020/039088A3
The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haemat...  
WO/2020/058458A1
The invention relates to certain substituted quinuclidine-3-one compounds for use in the treatment of hyperproliferative disease, such as cancer, and diseases associated with inflammation. More particularly, the present invention relates...  
WO/2020/039092A2
The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haemat...  
WO/2020/039094A1
The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haemat...  
WO/2020/039088A2
The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haemat...  
WO/2020/001304A1
The present invention falls within the field of medical technology, and in particular relates to a compound as shown in formula (I), and a pharmaceutically acceptable salt, ester or stereoisomer thereof, wherein R1, R2, X1, X2, X3, M, Ar...  
WO/2019/243850A1
This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M1 and M4 receptors. Also provided are pharmaceutical compositions...  
WO/2019/236699A1
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in th...  
WO/2019/223704A1
Provided are a class of fused-cyclic pyrazolone formamide compounds and a preparation method therefor, a pharmaceutical composition and the use thereof. Specifically, provided is a compound having the structure as shown in formula (I) (w...  
WO/2019/182938A1
Compounds and methods for preventing and/or treating one or more symptoms of sickle cell diseases (SCD) by administering at least one of the compounds are provided. The compounds are based on vanillin which is chemically modified to incr...  
WO/2019/173806A1
A method of treating a cancer in a patient includes obtaining a sample from the patient, using a C-circle assay to detect a presence of an alternative lengthening of telomeres (ALT) phenotype in the sample, and administering an effect am...  
WO/2019/126253A8
Disclosed are compounds of Formula (I) or salts thereof, wherein A, G, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmace...  
WO/2019/152946A1
Provided herein are compounds that are useful in the treatment of pain in a subject.  
WO/2019/121691A1
The present disclosure relates to compounds of Formula (I): (I) and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for...  
WO/2019/126253A1
Disclosed are compounds of Formula (I) or salts thereof, wherein A, G, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmace...  
WO/2019/122129A1
The present invention encompasses compounds of formula (I) wherein the groups R1 to R4, A and p have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds...  
WO/2019/126081A1
N-oxides, or salts thereof, wherein G, L2, R1, R5, R9, R10, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions...  
WO/2019/126113A1
Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, an...  
WO/2019/118799A1
Disclosed are compounds of Formula (I) (I) N-oxides, or salts thereof, wherein R1, G, A, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9...  
WO/2019/118528A1
Provided herein are compounds that modulate progranulin and methods of using the compounds in progranulin-associated disorders, such as Frontotemperal dementia (FTD).  
WO/2019/110521A1
The present invention relates to fluorophenyl substituted muscarinic receptor ligands with selectivity for M3 over M2 and to the use of these compounds in the treatment of various diseases such as asthma, chronic obstructive pulmonary di...  
WO/2019/105881A1
The invention relates to a novel and improved method for producing (3S)-3-(4-chlor-3-{[(2S,3R)-2-(4-chlorphenyl)-4,4,4-trifluor -3-methylbutanoyl]amino}phenyl)-3-cyclo-propylpropanoic acid of the formula (I), to the compound of the formu...  
WO/2019/086434A1
The present invention discloses a process for the preparation of 2-benzhydryl-3-quinuclidinone (1). (I). The process of the invention allows to obtain the intermediate 2-benzhydryl-3-quinuclidinone (1) by reaction of 2-benzylidene-3-quin...  
WO/2019/015690A1
A deuterated 3-quinuclidone compound, a preparation method, and a use. In particular, the present invention provides a compound shown in general formula I or a pharmaceutically acceptable salt, isomer or a mixture thereof, solvate, polym...  
WO/2018/220501A1
The present invention relates to a process for the preparation of a novel and versatile synthesis intermediate and its use in the preparation of umeclidinium. The invention also relates to some reference standards allowing to detect impu...  
WO/2018/210229A1
Disclosed are a series of α-7 nicotine acetylcholine receptor agonists, and specifically disclosed are compounds of formula (I), pharmaceutically acceptable salts thereof or tautomers thereof, and pharmaceutical uses thereof.  
WO/2018/193463A1
The present invention discloses an improved process for preparation of substantially pure pentamethylene bis(1-(3,4-dimethoxybenzyl)-3,4-dihydro-6,7- dimethoxy-1H-isoquinoline-2-propionate), a compound of formula I and its acid addition ...  
WO/2018/163212A1
Provided herein is a process for the preparation of umeclidinium bromide and intermediates thereof, wherein pure form of umeclidinium bromide is achieved by a two step process under mild conditions.  
WO/2018/157277A1
The present invention provides a compound of Formula (I), where in X is selected from the group consisting of CH and N; Q is selected from the group consisting of CH3 and H; R is selected from the group consisting of (II) and (III), or a...  
WO/2018/150437A1
Provided herein is a process for synthesis of aclidinium bromide and intermediates thereof, wherein the process for the preparation of aclidinium bromide increases the % yield of aclidinium bromide by about 70% to 90%.  
WO/2018/152368A1
Provided is a compound of Formula (I), wherein the variable groups are defined herein.  
WO/2018/108089A1
Provided are a class of compounds, as represented by formula (I), having a bifunctional active quaternary ammonium salt structure of a β2 adrenoreceptor agonist and an M receptor antagonist, a pharmaceutically acceptable salt, solvate, ...  
WO/2018/087561A1
The present invention discloses processes comprising a) reacting ethyl isonipecotate with 1 -bromo-2- chloroethane in the presence of an organic base in a solvent to form ethyl 1 -(2-chloroethyl)piperidine- 4-carboxylate (II) or a salt t...  
WO/2018/011611A1
The object of the invention relates to the salts of encenicline formed with inorganic and organic acids of general formula (I), as well as to the use of these for the production of pharmaceutical preparations primarily suitable for the t...  
WO/2018/011227A1
The invention relates to a compound of Formula I : Formula I, or pharmaceutically acceptable enantiomers, or salts thereof. The present invention also relates to the use of compounds of Formula (I) as selective inhibitors of tryptophan 2...  
WO/2017/218920A1
This invention is directed to asymmetric synthesis of funapide, which is useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.  
WO/2017/200184A1
The present invention relates to a novel chiral phase-transfer catalyst, and a method for preparing an α-amino acid by using the same. According to the present invention, an α-amino acid could be chirally synthesized in a high yield un...  

Matches 1 - 50 out of 3,176